AbbVie (ABBV)
(Delayed Data from NYSE)
$201.20 USD
-0.48 (-0.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.20 USD
-0.48 (-0.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Zacks News
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
by Zacks Equity Research
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.
This Combination of 3 Stocks Provides Monthly Income
by Derek Lewis
Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
by Zacks Equity Research
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.
Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
by Zacks Equity Research
AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.
4 Large Drug Stocks to Watch as IBD Market Gains Traction
by Kinjel Shah
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant
by Zacks Equity Research
J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).
ABBV vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABBV vs. LLY: Which Stock Is the Better Value Option?
Should You Invest in AbbVie (ABBV) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SDY
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.
4 Large Drug Stocks Likely to Sail Through Industry Woes
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley
by Zacks Equity Research
NVIDIA, Chevron, AbbVie, Alibaba Group Holding and Morgan Stanley are part of the Zacks top Analyst Blog.
Top Research Reports for NVIDIA, Chevron & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Chevron Corporation (CVX) and AbbVie Inc. (ABBV).
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
by Zacks Equity Research
Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.
Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SDY
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
The Zacks Analyst Blog Highlights AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank
by Zacks Equity Research
AbbVie, Exxon Mobil, Kontoor Brands, Select Water Solutions and Macatawa Bank are part of the Zacks top Analyst Blog.
Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.